Progress in the Treatment of Metastatic Melanoma

Published Online: Wednesday, September 26, 2012
Follow Pharmacy_Times:
In this podcast, a panel of experts discusses a range of topics relating to metastatic melanoma, including new treatment approaches, clinical trial updates, and managing side effects and pain. The participants on the panel were: Paul Chapman, MD, of the Memorial Sloan-Kettering Cancer Center; Gregory Daniels, MD, PhD, of the University of California San Diego; Mario Lacouture, MD, of the Memorial Sloan-Kettering Cancer Center; and Carolyn Messner, DSW, MSW, of CancerCare.
 
To listen to the podcast, click here.
Related Articles
Whereas previous research indicated that coffee consumption may protect against nonmelanoma skin cancers, a recent study suggested that drinking coffee could decrease a patient’s risk of developing malignant melanoma as well.
Community pharmacists play a significant role in helping patients to maintain the health of their skin.
The FDA has approved Merck’s Keytruda injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following administration of ipilimumab and, if positive for the BRAF V600 mutation, a BRAF inhibitor.
Despite advances in pain management and palliative care, intractable cancer pain remains a significant clinical, social, and financial burden in treating the oncologic population.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$